Heidelberg, Germany and Cambridge, UK, 17 June 2020 - 4basebio AG (Frankfurt: 4BSB; ISIN: DE000A2YN801; Prime Standard) announces the results of the Annual General Meeting (AGM) held today on June 17, 2020. The shareholders approved all resolutions proposed by the Management Board and Supervisory Board, published in the Federal Gazette on May 8, 2020, with a large majority.

Dr Heikki Lanckriet, CEO of 4basebio AG, said: "We would like to thank our shareholders for their trust and support in the reorientation of our company towards the field of innovative DNA production, a promising future market. We are also pleased that, following the successful share buyback program in April of this year, we have now received approval for a further buyback if this is appropriate."

The Company made use of the option provided by the German legislator in view of the coronavirus pandemic to conduct the ordinary AGM as a virtual meeting without the physical presence of shareholders or their proxies. Via a password-protected online platform, registered shareholders could exercise their voting rights before and during the AGM and submit questions until two days prior to the event. The AGM could be followed online in sound and vision.

Further information on the Annual General Meeting including the detailed voting results and the Management Board presentation can be found on the AGM 2020 page at: /annual-general-meeting/

About 4base bio:
4basebio AG, formerly operating under the name of Expedeon AG, is an enabler of exciting advances in medical science and patient care. After divestment of its immunology and proteomics products portfolio on January 1 2020, the Company changed its name to 4basebio AG reflecting the enhanced focus on technologies and products centered around DNA. The Company is focussing on DNA manufacturing to supply DNA products for therapeutic and other uses requiring large amounts of high-purity DNA, such as the fast-growing market of novel gene therapies and gene vaccines. Besides DNA manufacturing, 4basebio aims at providing research and diagnostic products based on its RNA reverse transcriptase, DNA polymerase and DNA primase enzymes, addressing the research tools and diagnostic products markets.
4basebio AG has offices in Germany, Spain, UK, and the US. The Company is listed on the Prime Standard segment of the Frankfurt Stock Exchange (Ticker: 4BSB; ISIN: DE000A2YN801).
More information:

***
For further information, please contact:

4basebio AG
Dr. Robert Mayer
Manager Investor Relations
T: 0
Email:
Investors' information: investors.4basebio.com

MC Services AG (Investor Relations and International Media Relations)
Julia Hofmann
Phone:
Email:

### This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy securities. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of 4basebio AG may deviate greatly from the established conclusions or implied predictions contained in such statements. 4basebio does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason. ###